Allied Market Research

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Forecast, 2014-2022


Portland, OR -- (SBWIRE) -- 07/06/2017 -- Acute Lymphocytic/Lymphoblastic leukemia is a kind of blood or bone marrow cancer. It occurs in lymphocytes which are white blood cells. It can then easily spread to the other parts of the body such as liver, spleen, lymph nodes and others. The number of cases of these diseases is rising at an alarming rate all over the globe. The rising incidence of acute Lymphoblastic/ Lymphocytic leukemia and innovative therapies related to it are the major drivers for Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market. Moreover, oncology market therapies are witnessing substantial growth due to unmet needs;this is also propelling the market. However, the high cost associated with the treatment of these diseases, unfavorable outcomes related to the treatment and lower capability of drug production are the major restraints of this market. The companies profiled in this report are GlaxoSmithKline Plc, Sigma-TauPharmaceuticals Inc., Erytech Pharma, Genzyme Corporation, Pfizer Inc, Talon Therapeutics, Inc. and (Spectrum Pharmaceuticals, Inc.).

Early buyers will receive 20% customization on this report.

The Acute Lymphocytic/Lymphoblastic leukemia market is segmented into types, drugs and geography. On the basis of types the Acute Lymphocytic/Lymphoblastic leukemia market is segmented into Acute Lymphocytic/Lymphoblastic Leukemia for child and Acute Lymphocytic/Lymphoblastic Leukemia for adult. Acute Lymphocytic/Lymphoblastic Leukemia for child holds the highest market share due to the rising incidence of these diseases in children as opposed to adults. On the basis of drugs, the market is segmented into pipeline drugs and existing drugs and they are further sub-segmented as well. On the basis of geography the market is segmented into various regions, namely, North America, Europe, Asia Pacific and LAMEA. The North American region holds the highest share in this market due to the rising incidence of Acute Lymphocytic Leukaemia in the United States.

Get PDF of this Report @


-In-depth analyses of the factors that limit and drive the growth of the market are provided

-Detailed analysis of various geographies would give an understanding of the trends in various regions so that companies can make region specific plans

-Deep dive analyses of segments such as types and drugs used will provide insights that would enable companies to gain competitive edge

-Porter's Five Force and other models would help in productive business decisions

-On-the-whole market analysis would assist in assessing the growth opportunities in this market


The global Acute Lymphocytic/Lymphoblastic leukemia Marketis segmented according to type, drugs and geography as follows:


-Acute Lymphocytic/Lymphoblastic Leukemia For Child
-Acute Lymphocytic/Lymphoblastic Leukemia For Adult


-Pipeline Drugs (Phase III)

-Inotuzumab Ozogamicin

-Existing Regimens/Drugs

-Hyper-CVAD Regimen
-Linker Regimen
-Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
-CALGB 8811 Regimen

By Geography

-North America
-Asia Pacific